CHAO CHENG to Neoadjuvant Therapy
This is a "connection" page, showing publications CHAO CHENG has written about Neoadjuvant Therapy.
Connection Strength
0.503
-
A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction. Sci Rep. 2022 02 09; 12(1):2211.
Score: 0.159
-
Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. Sci Rep. 2017 Nov 16; 7(1):15742.
Score: 0.119
-
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients. BMC Cancer. 2017 05 02; 17(1):306.
Score: 0.114
-
Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer. Genome Med. 2016 10 27; 8(1):114.
Score: 0.110